A Multi-Center, Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Pharmacokinetics, and Explore the Efficacy of Sofpironium Bromide Gel, 15% Applied Topically to Children/Adolescents, 9-16 Years, with Primary Axillary Hyperhidrosis

Main Article Content

Brandon Kirsch
Janet Dubois
Martin Zaiac
Sanjeev Ahuja
Deepak Chadha

Keywords

Hyperhidrosis, Sofpironium Bromide, Topical, Pediatrics, Adolescents, Safety, Tolerability, Pharmacokinetics

Abstract

Abstract not available.

References

1. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis; an update on prevalence and
severity in the United States. Arch Dermatol Res. 2016; 308:743-749.